Short answer
Praxis Precision Medicines, Inc. (PRAX) filed its Q3 2026 10-Q quarterly report on Nov 9, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$94M
- −27.5% YoY · −12.6% QoQ
- EPS (diluted)
- −$3.23
- +4.2% YoY · −12.2% QoQ
Source: XBRL data from the Praxis Precision Medicines, Inc. (PRAX) Q3 2026 10-Q on SEC EDGAR. USD.
Praxis Precision Medicines, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales since inception
- Net loss $94.2M vs $73.9M YoY, operating loss $106.9M vs $78.4M
- R&D $64.2M vs $65.8M, Cerebrum™ highest at $40.4M, Solidus™ $2.8M
- Cash, equivalents and marketable securities $1.3B, operating cash use $245.4M for nine months
- Ulixacaltamide PDUFA January 29, 2027, relutrigine updated to December 27, 2026, POWER1 endpoint failure headwind
Risk Factors
- No material changes from the December 31, 2025 Form 10-K risk factors
- Carried-forward risks include clinical development, regulatory approval, commercialization, financing, competition, and intellectual property challenges
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Praxis Precision Medicines, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.